JP2022504760A5 - - Google Patents

Info

Publication number
JP2022504760A5
JP2022504760A5 JP2021520113A JP2021520113A JP2022504760A5 JP 2022504760 A5 JP2022504760 A5 JP 2022504760A5 JP 2021520113 A JP2021520113 A JP 2021520113A JP 2021520113 A JP2021520113 A JP 2021520113A JP 2022504760 A5 JP2022504760 A5 JP 2022504760A5
Authority
JP
Japan
Prior art keywords
approximately
solvate
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504760A (ja
JP7513286B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/110904 external-priority patent/WO2020074010A1/zh
Publication of JP2022504760A publication Critical patent/JP2022504760A/ja
Publication of JP2022504760A5 publication Critical patent/JP2022504760A5/ja
Priority to JP2024099957A priority Critical patent/JP2024123152A/ja
Application granted granted Critical
Publication of JP7513286B2 publication Critical patent/JP7513286B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520113A 2018-10-12 2019-10-12 化学療法難治性がんの治療のための新しい併用薬方法 Active JP7513286B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099957A JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811195239.3 2018-10-12
CN201811195239 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099957A Division JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Publications (3)

Publication Number Publication Date
JP2022504760A JP2022504760A (ja) 2022-01-13
JP2022504760A5 true JP2022504760A5 (cg-RX-API-DMAC7.html) 2022-10-20
JP7513286B2 JP7513286B2 (ja) 2024-07-09

Family

ID=70163618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520113A Active JP7513286B2 (ja) 2018-10-12 2019-10-12 化学療法難治性がんの治療のための新しい併用薬方法
JP2024099957A Pending JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099957A Pending JP2024123152A (ja) 2018-10-12 2024-06-20 化学療法難治性がんの治療のための新しい併用薬方法

Country Status (16)

Country Link
US (2) US12257227B2 (cg-RX-API-DMAC7.html)
EP (1) EP3865130A4 (cg-RX-API-DMAC7.html)
JP (2) JP7513286B2 (cg-RX-API-DMAC7.html)
KR (1) KR102960038B1 (cg-RX-API-DMAC7.html)
CN (2) CN120168498A (cg-RX-API-DMAC7.html)
AU (1) AU2019357933B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006898A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115869A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190771A1 (cg-RX-API-DMAC7.html)
IL (1) IL282228B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004151A (cg-RX-API-DMAC7.html)
PH (1) PH12021550815A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103707TA (cg-RX-API-DMAC7.html)
TW (1) TWI848990B (cg-RX-API-DMAC7.html)
WO (1) WO2020074010A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102494B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
NZ602328A (en) 2010-03-19 2014-11-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4,9-二羟基-萘并[2,3-b] 呋喃新型酯
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2018511643A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル, インコーポレイテッド 癌を治療するための方法
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.

Similar Documents

Publication Publication Date Title
JP2022537551A5 (cg-RX-API-DMAC7.html)
RU2012147739A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
JP2021527092A5 (cg-RX-API-DMAC7.html)
JP2021512121A5 (cg-RX-API-DMAC7.html)
US20120157472A1 (en) Method for treating colorectal cancer
IL178745A (en) Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2020517696A5 (cg-RX-API-DMAC7.html)
JP2022509262A5 (cg-RX-API-DMAC7.html)
JP2012522837A5 (cg-RX-API-DMAC7.html)
JP2023527542A5 (cg-RX-API-DMAC7.html)
JP2014144962A5 (cg-RX-API-DMAC7.html)
JP2022550919A5 (cg-RX-API-DMAC7.html)
JP2023548055A5 (cg-RX-API-DMAC7.html)
JP2019506392A5 (cg-RX-API-DMAC7.html)
WO2017184086A1 (en) Method of treating liver cancer
JP2024016209A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
JP2005508323A5 (cg-RX-API-DMAC7.html)
JP2022520859A5 (cg-RX-API-DMAC7.html)
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
JP2022504435A5 (cg-RX-API-DMAC7.html)